Patent · US Active

TLE3 as a marker for chemotherapy

US7816084B2 · kind B2 · utility

7Cited by

1References

37Claims

0Family size

Assignee

APPLIED GENOMICS, INC. · US

Inventors

Brian Z. Ring · Foster City, US
Douglas T. Ross · Burlingame, US
Robert S. Seitz · Huntsville, US
Rodney A. Beck · Harvest, US

Key dates

Filing date	Nov 25, 2008
Grant date	Oct 19, 2010
Priority date	—
Expiry date	Dec 6, 2028

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/4703
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.